Aquatic Capital Management LLC Takes $539,000 Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Aquatic Capital Management LLC purchased a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 20,218 shares of the company’s stock, valued at approximately $539,000. Aquatic Capital Management LLC owned 0.07% of Castle Biosciences as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of CSTL. Covestor Ltd bought a new position in Castle Biosciences during the fourth quarter valued at $25,000. R Squared Ltd purchased a new position in shares of Castle Biosciences during the 4th quarter worth about $42,000. KLP Kapitalforvaltning AS bought a new position in Castle Biosciences during the 4th quarter valued at about $128,000. China Universal Asset Management Co. Ltd. raised its position in Castle Biosciences by 11.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock worth $158,000 after purchasing an additional 604 shares during the period. Finally, Oak Harvest Investment Services bought a new stake in Castle Biosciences in the fourth quarter worth about $206,000. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Trading Down 3.7 %

NASDAQ CSTL opened at $19.31 on Friday. Castle Biosciences, Inc. has a one year low of $16.97 and a one year high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The company has a market capitalization of $557.00 million, a price-to-earnings ratio of 96.55 and a beta of 1.11. The company’s 50-day simple moving average is $20.54 and its two-hundred day simple moving average is $26.29.

Insider Buying and Selling at Castle Biosciences

In related news, Director Daniel Bradbury sold 7,867 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Derek J. Maetzold sold 22,639 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $20.12, for a total transaction of $455,496.68. Following the completion of the transaction, the insider now owns 80,465 shares of the company’s stock, valued at $1,618,955.80. This represents a 21.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,321 shares of company stock valued at $774,644. 7.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CSTL shares. Robert W. Baird raised their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Guggenheim set a $30.00 target price on Castle Biosciences and gave the stock a “buy” rating in a research report on Friday, March 28th. Finally, Stephens restated an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $38.75.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.